Skip to main content

Table 4 Symptomatology reported in each group

From: Prevalence and implications of the presence of intraocular silicone oil droplets in patients treated with intravitreal injections of anti-VEGF

 

Non-Existent

N = 43

Scarce

N = 40

Moderate

N = 35

Abundant

N = 34

Significance among groups

Central scotoma

Yes (n, %)

N = 30

12 (27.9%)

7 (17.5%)

6 (17.1%)

5 (14.7%)

p = 0.452b

Scotoma discomfort (mean, SD)

6.92 (SD 0.88)

5.43 (SD 0.97)

5 (SD 1.36)

6.20 (SD 1.42)

p = 0.492a

Metamorphopsia

Yes (n, %)

N = 52

17 (27.9%)

13 (32.5%)

12 (34.3%)

10 (29.4%)

p = 0.815b

Metamorphopsia discomfort (mean, SD)

5.18 (SD 0.64)

5.69 (SD 0.72)

5.08 (SD 0.71)

5.90 (SD 0.87)

p = 0.890a

Floaters

Yes (n, %)

N = 60

17 (27.9%)

11 (27.5%)

21 (60%)

11 (32.3%)

p = 0.026b

Floaters discomfort (mean, SD)

3.29 (SD 0.56)

3.91 (SD 0.82)

3.33 (SD 0.45)

3.64 (SD 0.83)

p = 0.957a

  1. Statistically significant p < 0.05 in bold
  2. aKruskall-Wallis and Mann-Whitney U test
  3. bX2 test